Market Overview - On February 24, the Hong Kong stock market experienced fluctuations, with various indices showing declines: the China Securities Hong Kong Stock Connect Consumer Theme Index fell by 1.3%, the Hang Seng Technology Index decreased by 2.1%, the Hang Seng Hong Kong Stock Connect New Economy Index dropped by 2.5%, the China Securities Hong Kong Stock Connect Medical and Health Comprehensive Index declined by 3.1%, and the China Securities Hong Kong Stock Connect Internet Index fell by 3.3% [1] Fund Inflows - As of the last trading day before the holiday, the net inflows for the Hang Seng Technology ETF (E Fund, 513010) and the Hong Kong Stock Connect Internet ETF (E Fund, 513040) were 3.61 billion and 1.49 billion respectively over the past month [1] Sector Performance - According to Huatai Securities, there was an increase in market differentiation during the Spring Festival, with AI new forces and internet giants showing divergent trends. Despite positive consumer data, it did not significantly boost sector performance, with gains concentrated in technology and cyclical industries [1] Investment Outlook - Short-term advice for investors includes being cautious of the volatility risks associated with index adjustments and individual stock movements prior to the Hong Kong Stock Connect adjustments. For mid-term allocations, technology and cyclical materials remain clear main lines for investment [1]

从基本面看，创新药业绩预告验证产业景气。信达生物、荣昌生物和君实生物预告2025年收入约 110/32.5/25亿元，分别同比增长45%/89%/31.8% 国金证券认为，2-3月有望迎来创新药企业的业绩披露窗口，多家药企有望迎来减亏或扭亏，同时预计 2026年更多创新药企业有望扭亏并大幅释放利润；展望全年，AACR（4月）、ASCO（5月）、ESMO （10月）等学术会议上国产创新药有望进一步带来临床数据的兑现；整体上，创新药前期回调较为充 分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。 港股创新药上涨，截至发稿，港股通创新药ETF易方达(159316)涨2.89%，港股通医药ETF易方达 (513200)涨2.33%。 板块反弹主要受BD交易密集落地、预告业绩高增及流动性改善三重利好驱动。 创新药重磅BD频出：石药集团×阿斯利康：1月30日达成185亿美元合作（首付12亿美元），创中国药企 BD纪录； 信达生物×礼来：2月8日达成88.5亿美元合作（首付3.5亿美元），采用"端到端共研"模式； 2026年以来创新药BD首付款规模已超25年全年最高单季度水平，总交易金额达332.8亿美元（占25 ...

Group 1 - The Hong Kong stock market saw a rise in technology sectors such as integrated circuits and chips, with the Hang Seng New Economy Index, Hang Seng Technology Index, and CSI Hong Kong Internet Index all increasing by 1.1% [1] - The CSI Hong Kong Pharmaceutical and Health Comprehensive Index rose by 0.7%, while the CSI Hong Kong Consumer Theme Index experienced a slight decline of 0.1% [1] - Significant capital inflow was noted, with over 1.4 billion yuan net inflow into the E Fund Internet ETF (513040) and E Fund Hang Seng Technology ETF (513010) since the beginning of the year [1] Group 2 - According to CITIC Securities, the AI application sector is expected to be a key focus in early 2026, with ongoing catalysts for AI applications anticipated [1] - AI is gradually penetrating daily life, impacting various sectors including automotive, robotics, smart home devices, and wearables [1] - China is positioned advantageously in terms of the pace of application rollout and user scale, indicating substantial growth potential for AI applications [1]

Group 1 - The core viewpoint of the news highlights the divergence in the Hong Kong stock market, with consumer concepts showing strength while AI application sectors continue to adjust [1] - The CSI Hong Kong Stock Connect Consumer Theme Index rose by 1.7%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Index fell by 0.9%, the CSI Hong Kong Stock Connect Internet Index decreased by 1.0%, the Hang Seng Technology Index dropped by 1.2%, and the Hang Seng Hong Kong Stock Connect New Economy Index declined by 1.5% [1] - There has been a continuous inflow of funds, with the Hong Kong Stock Connect Internet ETF (513040) and the Hang Seng Technology ETF (513010) both receiving over 1 billion yuan in net inflows this year [1] Group 2 - According to CITIC Securities, the AI application sector is expected to be a main focus starting in early 2026, with multiple catalysts for AI applications anticipated in the future [1] - AI is gradually penetrating daily life through various hardware, including automobiles, robots, smart glasses, smart home devices, and wearables like smart rings and headphones [1] - On the software side, the upgrade in model inference capabilities is accelerating the deployment of enterprise-level Agentic AI, indicating significant growth potential for AI applications in China [1]

Group 1 - The core viewpoint of the news is that the Hong Kong stock market showed a mixed performance, with significant gains in the pharmaceutical sector and active performance in large internet stocks, as evidenced by the rise in various indices [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 4.0%, while the CSI Hong Kong Stock Connect Internet Index rose by 1.3%, and the Hang Seng New Economy Index increased by 1.0% [1] - The market sentiment and liquidity environment are currently better than in November, leading to an increased probability of successful investments in Hong Kong stocks [1] Group 2 - Huatai Securities suggests continuing to allocate investments in technology chains with performance expectations, as the liquidity environment may catalyze significant growth in the next quarter [1] - The report emphasizes the need for balanced allocation in cash flow assets considering changes in driving factors and funding attributes [1]